Dominique Bonnet

TL;DR: It is demonstrated that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) — termed the SCID leukemia-initiating cell, or SL-IC — possesses the differentiate and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell.

TL;DR: A newly discovered human repopulating cell is identified that initiates multilineage hematopoiesis in NOD/SCID mice and demonstrates complexity of the organization of the human stem- cell compartment and has important implications for clinical applications involving stem-cell transplantation.

TL;DR: It is suggested that the engraftment process requires pluripotent stem cells plus accessory cells or cytokine treatment which act early after transplantation, and the NOD/SCID xenotransplant system provides the means to further clarify the processes underlying human stem cell engraftments.

TL;DR: Examination of the effect of long-term in vivo treatment with various combinations of human cytokines on the developmental program of the SCID-repopulating cell shows that the lineage development of the human graft in NOD/SCID mice can be modulated by administration ofhuman cytokines, providing a valuable tool to evaluate the in vivo action of humanocytes on human repopulating cells.

TL;DR: In this paper, human hemotopoietic stem cells are characterized as CD34-Lin and CD34 -CD38-Lin, and methods of isolating and using such cells in compositions and in methods for the reconstitution of a deficient or missing cell population.